Compare Ascendis Pharma A/S (ASND) vs iShares MSCI Canada (TSX) (EWC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares MSCI Canada (TSX) — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while iShares MSCI Canada (TSX) trades at $58.47. Which is the better fit depends on your goals.
| ASND | EWC | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $277.18 | $59.46 |
52-Week Low | $163.32 | $45.86 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
EWC trades at $58.65, up 0.46% today, with a bullish technical signal from moving averages. The stock shows strong momentum near key resistance at $59, supported by Canada's economic recovery and trade surplus expansion. A dividend of $0.28 is scheduled for June 2026, adding income appeal. However, RSI levels indicate potential overbought conditions, and financial ratios remain undisclosed, limiting fundamental clarity.
Outlook is cautiously optimistic, driven by Canada's economic tailwinds and technical strength, but risks include trade policy uncertainty and valuation opacity. Investors should monitor earnings reports for fundamental validation amid neutral analyst sentiment and macroeconomic sensitivities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →
